Metabolism Disorder TRIZ Cases

See how copper-ion-releasing textiles promote beneficial bacteria, manage body weight, and enha

See how a multi-herb extract composition replaces insulin and synthetic drugs with oral herbal

An oral Cyclocarya-based herbal extract addresses inconvenient diabetes therapy by lowering blood sugar with fewer side effects.

Patient-question rules generate personalized insulin pump settings, reducing manual therapy effort while supporting steadier glucose control.

Rule-based patient questioning generates personalized basal, correction, and carb-ratio settings to simplify insulin pump therapy.

A selected Lactobacillus kefiri strain combines acid, bile salt, phenol, and antibiotic resistance with adhesion and cholesterol lowering.

Patient-specific questions feed a rule module that suggests basal rates and ratios, reducing insulin pump setup complexity.

Fixed-size audio segments carry entry-point metadata so decoders can isolate lost segments, preserve frame timing, and recover audio quality.

Maps variable-length audio frames into fixed segments with boundary headers so lost segments do not corrupt whole frames or audio timing.

Maps variable-length compressed audio frames into self-contained fixed segments to limit error loss and preserve synchronization.

An in vitro HEK-293 assay maps α-Gal A mutations to DGJ responsiveness, enabling faster selection of Fabry chaperone therapy.

Low-dose IL-2 selectively expands Tregs without triggering effector T cells, helping control type 1 diabetes inflammation with minimal side effects.

Low-dose IL-2 expands suppressive Tregs without substantially activating effector T cells, reducing lupus inflammation and autoimmune responses.

Nitrite-spiked dialysate delivers sodium nitrite across the dialyzer membrane to maintain physiological nitrite levels during hemodialysis.

Chiral separation isolates the active pyridazinone enantiomer to improve THR-β selectivity and treat NAFLD and NASH with fewer cardiac effects.

Targeting HIF1α and PFKFB3 helps remove dysfunctional β-cells and regenerate healthy ones to improve insulin sensitivity in type 2 diabetes.

By modulating SREBP1, a CPNE7-based composition limits liver lipid droplets and inflammatory cell buildup in NAFLD treatment.

Chemical modifications to GLP-1 and glucagon dual agonist peptides improve proteolytic stability and half-life for once-weekly treatment.

A tirzepatide formulation uses NaCl, propylene glycol, and dibasic sodium phosphate to improve shelf-life and injection site experience.

Neutralizing GDF15 with high-affinity monoclonal antibodies helps block immune suppression and inhibit tumor growth in mouse models.

AAV-driven FGF21 expression in the hypothalamus extends therapeutic action while limiting off-target organ exposure and frequent dosing.

PLLA and PLGA scaffolds carrying GLUT4-overexpressing myoblasts improve glucose uptake and help restore normoglycemia in diabetes.

A high-purity EPA ethyl ester composition lowers triglycerides in moderate to severe hypertriglyceridemia without raising LDL-C or non-HDL-C.

A breast-milk-like lipid emulsion lowers phytosterols to reduce cholestasis and liver dysfunction in parenteral nutrition for neonates.

Combining GLP-1 and GIP activity in a long-acting polypeptide improves glycemic control and weight reduction with fewer GI side effects.

Subcutaneous exendin(9-39) blocks GLP-1 signaling to prevent severe post-bariatric hyperinsulinemic hypoglycemia without pancreatectomy.

Hydrogel microcapsules encapsulate islet cell structures with biocompatible polymer blocks to limit immune rejection and improve engraftment.

A butein, sulfuretin, and isoliquiritigenin composition improves glucose regulation in diabetes while addressing side effects seen with current therapies.

Small-molecule heterocyclic GLP-1R agonists address peptide dosing and bioavailability limits while preserving insulin-secretion activity.

Gradual weekly tirzepatide dose escalation improves glycemic control and weight management while limiting gastrointestinal adverse events.

A hydrotrope boosts SNAC solubility in an oral GLP-1 composition, enabling faster uptake and improved bioavailability within 15-30 minutes.

Combining GLP-1R agonists with ACC, DGAT2, KHK, or FXR modulators improves NASH treatment by reducing steatosis, inflammation, and fibrosis.

Anti-PCSK9 antibodies block PCSK9 to preserve LDL receptor recycling and lower LDL-C when statins are inadequate or not tolerated.

A staged, serum-free route converts expanded potential stem cells through trophoblast cells to MSCs, improving yield, cycle time, and purity.

CRISPR/Cas editing of the PCSK9 gene enables durable inhibition beyond antibodies or RNAi, increasing LDL receptors and lowering LDL cholesterol.

PEPITEM redirects leukocyte trafficking to reduce obesity-linked inflammation and protect pancreatic beta-cells from damage.

Non-human IAPP peptide variants block human amyloid aggregation and protect cells from toxicity in type 2 diabetes treatment.

AAV-delivered BDNF expression in the hypothalamus enables sustained weight loss without the adverse effects and repeat injections of obesity drugs.

Dynamic PBA-diol binding creates a subcutaneous insulin reservoir that enables fast high-glucose release and slow basal release for week-long control.

A seven-strain probiotic consortium boosts phytase activity to reduce phytic acid and release iron, zinc, magnesium, and L-lysine from cereal foods.

Pretransplant gem-difluorinated C-glycopeptides help isolated pancreatic cells resist inflammation and drug toxicity, improving graft survival.

Controlled crystallization yields a single-phase pyrrole amide Form I with low hygroscopicity, better stability, and improved bioavailability.

A triglyceride-surfactant self-emulsifying formulation improves liver uptake, micellar solubilization, and pharmacokinetic consistency.

Solid- and solution-phase Fmoc synthesis improves GLP-1 agonist purity while making liraglutide and semaglutide production scalable.

Oral migalastat dosing improves cardiac and renal markers in Fabry disease while avoiding the slow response and immune issues seen with ERT.

An elevated syringe support and actuated tube clamp use gravity to ease one-handed infusion and help prevent needle displacement.

Quinoline compounds combine selective FGFR4 binding with covalent cysteine targeting to extend inhibition and reduce resistance.

An IgG4 anti-GDF15 antibody regimen boosts tumor T-cell entry and checkpoint inhibitor efficacy while avoiding ADCC and CDC toxicity.

C1-C4 alkyl ester azelates improve LDL, HDL, and glucose metabolism, helping address dyslipidemia with insulin resistance and cardiovascular risk.

High-dose monthly PCSK9 antibody dosing maintains LDL-C lowering without statins, improving adherence and target attainment.

An ADAMTS1-derived M3 mutant peptide helps counter muscle loss, fat gain, and impaired glucose metabolism linked to aging and inactivity.

Engineered VHH polypeptides bind MC4R with high affinity to reduce off-target melanocortin receptor activation and support weight-loss therapy.

Targeted fish oil, L-arginine, and vitamin blends help retain amino acids and limit muscle wasting in renal disease.

A dual GLP-1/GIP agonist formulation uses propylene glycol and phosphate buffer to prevent degradation and polymerization without antimicrobial agents.

Neutralizing DBI with antibodies or immunization lifts autophagy inhibition and shifts metabolism toward weight loss and lower food intake.

Oil-based carriers keep GLP-1 agonist microspheres stable in suspension, improving dissolution, bioavailability, and injection convenience.

Anti-IL-2 antibodies reduce IL-2 receptor binding to suppress CD8+ T cells while preserving regulatory T cell activity for autoimmune therapy.

Mixed-serotype VP1, VP2, and VP3 capsids improve AAV transduction while reducing neutralizing antibody response and dose burden.

A porous biodegradable nanofiber microwell improves nutrient and oxygen diffusion, supports insulin cell differentiation, and enables in situ transplantation.

By stabilizing lysosomal membranes through Hsp70-BMP binding, this case shows a route to restore enzyme activity in lysosomal storage diseases.

A multi-excipient anti-ANGPTL3 formulation balances high concentration, storage stability, and low syringe viscosity for subcutaneous dosing.

Alkyl glycosides such as DDM suppress fibrous aggregate formation in GLP-1 liquid formulations, improving storage stability for injectables.

Cross-linking ALK1 with BMPRII or activin receptors boosts SMAD signaling to address endothelial dysfunction and vascular malformations in HHT.

Gentler ultrafiltration, differential centrifugation, and spray-drying raise PDV yield, avoid aggregation, and preserve activity for storage.

Bitter whey-derived oligopeptides use enteric delivery to activate gut TAS2R receptors and trigger GLP-1 and PYY release for glucose control.

Modular cinnamic amide derivatives expand FXR agonist diversity while maintaining activation for bile acid, lipid, and glucose regulation.

Enteric controlled-release larazotide targets the jejunum and ileum to preserve tight junctions, limit permeability, and reduce inflammation.

An oral mimetic composition activates AMPK by raising AMP and AMP/ATP ratios, helping prevent prediabetes without strict diet adherence.

Hydrophobic amino acids in biodegradable microspheres suppress burst drug release, improve suspension, and prevent injection clogging.

Direct CNS delivery of leptin regulates glucose metabolism without insulin, improving blood glucose control and reducing patient burden.

PEG-tuned VLA-4 inhibitors extend hematopoietic stem cell mobilization beyond 4 hours, enabling single-day collection with CXCR4 combinations.

Stable G6PC genome integration using CRISPR/Cas9 overcomes AAV loss and sustains glucose-6-phosphatase expression in metabolic liver disease.

Covalently attached fatty acid helps IL-22 stay in circulation longer while preserving receptor engagement and efficacy in metabolic, gut, and liver disease.

A two-stage plant peptide extract targets MAPK and IRS/PI3K/Akt pathways to lower blood glucose, blood pressure, and blood lipids.

A diastereomeric α-anordrin approach relieves estrogen-deficiency symptoms while lowering cancer risk and reducing side effects in combination therapy.

Peptide linkers directly connect an scFv and monoclonal antibody to balance T-BiAb stability, binding affinity, expression, and intact-protein production.

Conventional diets may meet basic nutrition without sufficient IMF deposition; this feed uses controlled fatty acids and functional ingredients to improve marbling.

During pediatric weight recovery, intact bovine milk-derived exosomes help increase lean body mass and reduce disproportionate fat accumulation.

Reduced SMCT1, MCT1, and MCT4 expression limits butyrate use; SF68 pre-conditioning helps restore uptake and intestinal tight junctions.

By activating GLP-1 receptors, semaglutide supports glycaemic control while reducing MACE risk in high-risk type 2 diabetes.

Perinatal and T regulatory cells suppress autoimmune beta-islet destruction, helping preserve insulin production before diabetes develops.

Omega-3 fatty acids, protease inhibitors, and absorption enhancers help oral insulin retain activity and cross the intestinal barrier.

Targeting c-Rel at serine 350 reduces cytokine expression without broad immune suppression in autoimmune disease and cancer.

This stabilized combination extends action and supports subcutaneous diabetes treatment twice weekly or less often.

This case uses PAD4 inhibitors and DNase to remove harmful NETs, reducing fibrosis while supporting wound healing and organ function.

Acetate or citrate buffers with tonicity modifiers help limit exendin (9-39) aggregation while supporting higher exposure and longer action.

Administering TNF-alpha modulators regulates signaling pathways to treat polycystic kidney disease by addressing underlying molecular causes of cyst growth.

Capillary zone electrophoresis resolves charge heterogeneity in recombinant heparan N-sulfatase to ensure batch consistency and bio-efficacy.

Solid phase synthesis replaces complex biological methods, reducing waste and purification steps while increasing yield.

Combining anti-c-Met and anti-Ang-2 antibodies inhibits angiogenesis through synergistic action.

CRISPR-edited mesenchymal stem cells secrete IL-10 and Reg proteins to reduce immune rejection and promote beta-cell regeneration in type 1 diabetes grafts.

Antibodies targeting the GFRAL receptor block GDF15-induced signaling, resolving the unknown mechanism bottleneck in cachexia therapy.

Systematic parameter changes in GPAT inhibitor structures enable targeted therapeutic control over phospholipid synthesis for MYC-driven cancers.

Recombinant dermatopontin addresses limited effectiveness of current metabolic disease treatments by enhancing energy expenditure and reducing weight gain.

Recombinant human acid ceramidase replaces complex stem cell transplantation by directly degrading toxic ceramide, reducing spleen weight and lipogranulomas.

Bicyclic peptides activate guanylate cyclase C receptors to boost cyclic GMP production, enhancing intestinal fluid secretion and motility.

Val-Pro-X peptides from casein hydrolysates inhibit dipeptidyl peptidase-IV, avoiding complex synthetic processes and safety verification challenges.

Liposome-encapsulated mRNA encoding ornithine transcarbamylase enables sustained protein production, resolving surgical risks of liver transplantation.

Segmenting the MRJP3 protein isolates a 125mer peptide that lowers blood lipids and glucose to address insufficient efficacy in conventional treatments.

Laminated optical sensor transduces interstitial analyte concentrations via visible light, eliminating invasive blood draws and improving patient compliance.

Segmenting amorphous dapagliflozin and metformin into distinct layers overcomes diffusion barriers while maintaining blood glucose control.

A homeopathic medicinal product combining eight active ingredients to reduce body weight.